

## Notice of Changes to 340B Prices

10/30/2024

Pursuant to 42 C.F.R. § 447.510(b), Eli Lilly and Company (Lilly) has submitted routine updated 3Q2021 Average Manufacturer Prices and Best Prices for certain of its covered outpatient drugs to the Centers for Medicare & Medicare Services (CMS) to account for lagged transactional data. These restated Medicaid prices result in both upward and downward adjustments to 1Q2022 340B Ceiling Prices.

*Table 1: Products Subject to Upward Adjustments to the Previously Reported Ceiling Price*

| NDC         | Product Description                   |
|-------------|---------------------------------------|
| 00002143611 | EMGALITY 120 MG 1.000000 MILLILITER   |
| 00002237711 | EMGALITY 120 MG 1.000000 MILLILITER   |
| 00002831501 | HUMULIN N 100UCD 10.000000 MML        |
| 00002831517 | HUMULIN N 100UCD 3 MILLILITER         |
| 00002144511 | TALTZ 80 MG 1.000000 MILLILITER       |
| 00002144527 | TALTZ 80MG 2 MILLILITER               |
| 00002144509 | TALTZ 80MG 3 MILLILITER               |
| 00002143380 | TRULICITY 0.75 MG 2.000000 MILLILITER |
| 00002143480 | TRULICITY 1.5MG 2.000000 MML          |

Lilly has elected not to seek recoupment of these underpayments from Covered Entities.

*Table 2: Products Subject to Downward Adjustments to the Previously Reported Ceiling Price*

| NDC         | Product Description                  |
|-------------|--------------------------------------|
| 00002880559 | HUMULIN N PEN 100UCD 15 MILLILITER   |
| 00002821501 | HUMULIN R 100UCD 10.000000 MML       |
| 00002772411 | TALTZ 80 MG 1.000000 MILLILITER      |
| 00002223680 | TRULICITY 3 MG 2.000000 MILLILITER   |
| 00002318280 | TRULICITY 4.5 MG 2.000000 MILLILITER |

**Lilly uses wholesaler chargeback records to calculate and automatically issue refund payments to impacted eligible Covered Entities at the address listed in the HRSA database.**

Lilly does not directly contact or automatically issue checks to Covered Entities who may be eligible for amounts less than \$1.00 resulting from this restatement. For these de minimis changes, Lilly is offering to refund such Covered Entities through this Notice.

Covered Entities who believe they may be entitled to a refund amount less than \$1.00 for purchases of the above listed products in 1Q2022 or have questions about refunds Lilly already issued may contact Lilly at [basesupport\\_cma@lilly.com](mailto:basesupport_cma@lilly.com) with "Attn: 340B Recalculation" in the subject line to confirm any applicable amounts at issue and to initiate the payment process.

Lilly has requested that the Health Resource and Services Administration (HRSA) post this Notice on the HRSA public website to ensure transparency to Covered Entities regarding Lilly's recalculation and refund process.

\*\*\*